Neuren Pharmaceuticals stock

NEU · ASX · AUD

Compare Neuren Pharmaceuticals
$20.97Change from previous close: −4.73%Absolute change: −$1.04

Close · November 20, 2026

Price history

+13.41% over the period

1 year: from $18.49 (November 20, 2025) to $20.97 (November 20, 2026), +13.41%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$20.97
October 30, 2026$20.36
September 30, 2026$20.35
August 31, 2026$19.74
July 31, 2026$18.00
June 30, 2026$17.75
May 29, 2026$14.54
April 30, 2026$12.46
March 31, 2026$11.81
February 27, 2026$13.05
January 30, 2026$16.69
December 31, 2025$18.61
November 28, 2025$19.64
November 20, 2025$18.49

At a glance

  • The company

    Biopharmaceutical company developing drugs for neurological disorders including Rett syndrome, Fragile X syndrome and other rare genetic conditions

  • Latest results

    Quarter to June 30, 2026 · EPS $0.04 (estimate $32.00)

TickerLandia's take on Neuren Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$11.00
52-wk high$24.55

−14.58% from the 52-week high

Analysts · 6 analysts

Average target$27.03+28.91% vs. price

Buy 6 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Neuren Pharmaceuticals

Compared with similar companies: very high price.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Neuren Pharmaceuticals is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Neuren Pharmaceuticals's P/E today is 90.1, above the median of its last 5 fiscal years (45.2; between 11.5 and 91.4 from 2017 to 2025). Neuren Pharmaceuticals's P/E (trailing 12 months): 144.0, +111% against the median of a group of 6 similar companies (68.2).

P/E compared with its history

Compared with 6 similar companies

Neuren Pharmaceuticals's metrics compared with similar companies
MetricNeuren PharmaceuticalsPosition in the groupBand
P/E (trailing 12 months)144.0High
Forward P/E36.1Middle
Operating margin19.9%Middle
ROE6.2%Middle
Price/book8.21High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Neuren Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$33.16M

Latest quarter · Q2 2026

Net income

$4.85M

Latest quarter · Q2 2026

Quarterly net margin

14.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$2.74B
P/E
144.0
EPS
$0.15
Volume
37.24K
Daily trading
€6.45M
Dividend yield
0.72%
Last ex-dividend on September 15, 2026

How Neuren Pharmaceuticals is changing

All results
  • Revenue grew 146.0% a year on average over the last 5 years

  • Operating margin rose from −4.7% to 34.1%

  • Profits turn into cash: free cash flow equal to 91% of net income

Returns

Neuren Pharmaceuticals returns with dividends

$1,000 invested in Neuren Pharmaceuticals 5 years ago, on November 22, 2021, would be worth $11,397 today: +1,039.67% in total, +62.79% per year. This is the price return only: dividends are excluded.

PeriodNeuren PharmaceuticalsS&P/ASX 200$1,000 becomes
1 month+6.88%−2.54%$1,069
6 months+68.84%+1.13%$1,688
Year to date+12.68%−1.40%$1,127
1 year+14.23%+0.47%$1,142
3 years+42.07%+21.74%$1,421
5 years+1,039.67%+16.86%$11,397
10 years+1,488.64%+60.57%$15,886

Over the last 6 months it has done better than 95% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P/ASX 200: price only. Calculate your investment

The chart in detail

Neuren Pharmaceuticals: technical analysis

Neuren Pharmaceuticals is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 16.5% below its all-time closing high ($25.11, December 28, 2023).

Trend
Upward
RSI (14 sessions)
45
Between 30 and 70
vs 200-session average
+26.69%

Support and resistance

Price areas where Neuren Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$21.07+0.46%3 touches, last on September 17, 2026
  2. Last price$20.97
  3. Support$20.22−3.60%2 touches, last on December 23, 2025
  4. Support$19.46−7.18%3 touches, last on September 29, 2026
  5. Support$18.59−11.34%5 touches, last on October 27, 2026

Volatility and risk

Over the last year it has moved more than the S&P/ASX 200.

Beta (1 year) vs S&P/ASX 200
1.83
Volatility (60 sessions, annualised)
46.3%
Largest fall in the last year
−44.89%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Neuren Pharmaceuticals: seasonality

Average monthly price change over 22 years

+2.3%Jan−6.2%Feb−4.8%Mar+34.2%Apr+2.7%May−2.6%Jun+10.3%Jul−4.0%Aug+1.3%Sep+10.9%Oct+7.3%Nov+3.5%Dec

Over the last 22 years, the strongest month for Neuren Pharmaceuticals has been April: +34.24% on average, positive in 11 years out of 22. The weakest has been February: −6.20% on average, positive in 6 years out of 21. November, the current month, has been positive in 13 years out of 21 (+7.27% on average).

Show chart data
MonthAverageMedianPositive years
January+2.31%−2.64%7 of 21
February−6.20%−5.88%6 of 21
March−4.82%−6.14%7 of 22
April+34.24%+0.31%11 of 22
May+2.66%0.00%10 of 22
June−2.63%−4.19%8 of 22
July+10.29%+5.46%15 of 22
August−3.98%−2.34%8 of 22
September+1.32%−3.17%10 of 22
October+10.94%+5.72%14 of 22
November+7.27%+9.14%13 of 21
December+3.52%−0.63%10 of 21

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Neuren Pharmaceuticals and its competitors

With eight employees and revenue of AUD 64.6 million in the fiscal year ended December 2025, Neuren Pharmaceuticals develops drugs for neurological disorders. It develops and commercializes DAYBUE (trofinetide) for Rett syndrome in adults and in patients aged 2 years and older, and runs a Phase 2 trial for Fragile X syndrome. Its NNZ-2591 compound has completed Phase 2 testing for Phelan-McDermid syndrome, is in Phase 2 for Angelman and Pitt Hopkins syndromes, and is in preclinical stage for Prader-Willi syndrome, hypoxic ischemic encephalopathy and SYNGAP1.

Headquarters
Hawthorn East, Australia
Employees
8
Founded
2001
Chief executive
Jonathan Pilcher
Neuren Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Neuren PharmaceuticalsNEU$1.83B19.9%144.0+68.84%
MesoblastMSB$1.48B-42.6%—−14.82%
InSilico Medicine Cayman TopCo3696$2.59B-6.9%—−36.46%
Telix PharmaceuticalsTLX$2.92B6.2%92.3−7.71%
Metis TechBio7666$1.11B-131.2%—−63.08%
3SBio1530$4.56B60.3%3.90−34.08%

Same industry or related industries, similar size. Compare Neuren Pharmaceuticals with its competitors · Full profile